查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1250769

到 2028 年的眼科治疗市场预测——按适应症、药物类别、剂型、分销渠道、最终用户和地区进行的全球分析

Ophthalmic Disease Therapeutics Market Forecasts to 2028 - Global Analysis By Disease Indication, Drug Class, Dosage Form, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC，2022年全球眼科药物市场规模将达到335.6亿美元，2028年将以8.4%的复合年增长率增长，达到544亿美元，预计将达到4000万美元。

眼科药物包括用于治疗各种眼部疾病（例如青光眼、干眼症和视网膜疾病）的药物和药物。 这些疾病在人群中日益流行，以及这些疾病造成的医疗保健负担不断增加，预计将增加对新药和疾病管理方法的需求。

根据威尔士政府发布的 2021 年报告，威尔士的眼保健从业者人数从 2020 年 3 月的 885 人增加到 2021 年 3 月的 961 人。

市场动态

驱动程序

眼疾患病率上升

青光眼、视网膜疾病和干眼症等眼病在人群中的患病率不断上升，是全球患病率不断上升的主要驱动因素之一。 各种眼病的患病率在老年人群中更高。 各种医疗保健组织、政府机构和市场进入者加大力度，提高了人群的诊断率和治疗率。

约束

生物製剂成本高

生物製剂和生物仿製药具有多种临床益处，例如提高疗效和提高安全性。 然而，也存在一些局限性，例如生物製剂的高成本和高自付费用。 由于生物製剂的诸多优点以及与其研究、开发和批准相关的各种成本，高成本是限制这些药物在发展中国家使用的一个重要问题。

机会

创新药物和疗法的临床试验和候选管道数量增加

市场先驱和研究机构专注于开发创新疗法并将其推向市场以治疗疾病。 在预测期内，市场对眼科药物的需求预计将增长，因为市场进入者专注于研发活动以开发治疗这种疾病的新药。 市场上主要竞争对手发现和推出新药以满足不断增长的患者群体未满足的需求的重点和活力预计会增加眼科药物的消费。

威胁

认知度低

市场扩张受到严格的监管框架和模棱两可的报销做法的阻碍。 市场增长受到农村地区对各种眼部问题认识不足以及缺乏针对所有类型的人工晶状体和隐形眼镜的医疗保险的限制。 眼保健已经变得非常昂贵，全世界许多人无法获得眼保健。 这被认为是全球眼药市场增长放缓的主要原因。

COVID-19 的影响

在整个预测期内，COVID-19 对市场增长产生了负面影响。 大流行期间减缓市场增长的主要因素之一是骨科诊所的临时关闭以及医疗保健提供者对 COVID-19 患者的关注。 由于地方政府当局实施封锁限制，许多眼科保健服务已被取消或推迟，患者到医院和诊所就诊的次数也有所减少。 因此，全球患者对眼科药物的需求下降。

预计抗 VEGF 区域在预测期内最大

由于需求和接受度的增加，以及拥有广泛产品组合的强大市场参与者的存在，预计抗 VEGF 药物将实现有利增长。 此外，该细分市场的增长归功于 Avastin、LUCENTIS 等的卓越表现。 当前一类抗 VEGF 药物有效但不持久，导致越来越多的参与者专注于开髮长效疗法。

预计在预测期内，半固态部分的复合年增长率最高

由于软膏、悬浮液和凝胶等产品的批准和上市不断增加，预计半固体部分在预测期内将以最快的复合年增长率增长。 软膏剂由于其在治疗炎症性疾病、感染性疾病和干眼症方面的高效性，其用途正在扩大，并且半固体产品的采用正在增加。 此外，各大公司对获得批准和推出新产品的兴趣日益浓厚，也有助于该领域的扩展。

市场份额最高的地区

由于各种眼病的患病率上升以及诊断和治疗率的提高，预计亚太地区在预测期内将占据最大的市场份额。 此外，该地区在眼科和眼保健方面不断增加的支出，以及对一系列眼病的负担得起的报销，导致该地区主要国家的先进和新疗法得到推广。 众多治疗眼科疾病的创新药物研发的有利环境和新药审批的进展也是促进市场增长的因素。

复合年增长率最高的地区：

预计欧洲在预测期内的复合年增长率最高。 增加用于治疗各种眼部疾病的生物製剂和生物仿製药的上市，强调有效的眼部疾病管理，并扩大市场主要参与者的尝试以扩大其地理足迹。 特别是，新产品的推出是对市场增长做出重大贡献的少数几个方面之一。 此外，政府投资的增加和医疗基础设施的进步正在提振市场。

主要发展

2022年9月，Santen Pharmaceutical Co., Ltd.（以下简称“Santen Pharmaceutical Co., Ltd.”）与UBE联合宣布“欧姆龙茶（Omidenpag异丙基滴眼液）0.002%”获批用于原发性开角型青光眼或获批被美国FDA批准为降低高眼压症患者升高的眼内压的适应症。

2022年6月，F. Hoffmann-La Roche（以下简称“F.HL”）获得加拿大卫生部批准用于治疗新生血管性年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（Babismo获批用于治疗获得了 DME)。

2022 年 3 月，Novartis公司的眼科药物 Beovu 获得欧盟委员会的批准，用于治疗糖尿病性黄斑水肿引起的视力障碍。

2022 年 2 月，Viatris Inc. 获得批准用于治疗眼部炎症的 0.05% 环孢菌素眼用乳剂，这是艾尔建 (Allergan) 的 Restasis 的第一个仿製药。

2021 年 12 月，Abbvie公司获得了美国 FDA 批准的老花眼治疗药物毛果芸香碱盐酸盐眼用溶液 Vuity。

这份报告提供了什么

  • 按地区和国家/地区划分的市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议等）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局和趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 对其他市场参与者（最多 3 个）进行全面分析
    • 主要参与者的 SWOT 分析（最多 3 人）
  • 区域细分
    • 应客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：通过可行性检查）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球眼科药物市场：按适应症分类

  • 视网膜疾病
    • 糖尿病性黄斑水肿 (DME)
    • 视网膜静脉阻塞 (RVO)
    • 糖尿病性视网膜病变 (DR)
    • 黄斑变性 (AMD)
  • 青光眼
    • 开角型青光眼
    • 闭角型青光眼
    • 其他
  • 干眼症
  • 过敏和感染
  • 其他适应症

第 6 章全球眼科药物市场：按药物类别分类

  • 抗青光眼
    • α 肾上腺素激动剂
    • β受体阻滞剂
    • 碳酸酐□抑製剂
    • 联合代理
    • 前列腺素类似物
    • 其他
  • 抗VEGF
  • 抗炎药
  • 抗感染
  • 其他药物类别

第 7 章全球眼科药物市场：按配方分类

  • 半固态
  • 固体
  • 液体

第 8 章全球眼科药物市场：按分销渠道

  • 零售店和在线药店
  • 医院药房

第 9 章全球眼科药物市场：按最终用户分类

  • 耐心
  • 诊断中心
  • 医院
  • 眼科

第 10 章全球眼科药物市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第11章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals Inc.
  • AbbVie Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Viatris Inc.
  • Novartis AG
  • Eye Pharmaceuticals
  • Roche Valeant
  • Merck & Co.
  • Lpath
  • Alcon Inc.
  • Pfizer Inc.
  • Senju
Product Code: SMRC22646

According to Stratistics MRC, the Global Ophthalmic Disease Therapeutics Market is accounted for $33.56 billion in 2022 and is expected to reach $54.44 billion by 2028 growing at a CAGR of 8.4% during the forecast period. Ophthalmic illness therapeutics comprise medications and therapies used to treat a variety of ocular ailments such as glaucoma, dry eye disease, retinal diseases, and others. The expanding prevalence of these disorders in the population, together with the rising healthcare burden caused by these conditions, is predicted to increase demand for novel medicines and approaches to disease management.

According to the 2021 report published by the Welsh Government, the number of ophthalmic practitioners in Wales increased to 961 in March 2021 from 885 in March 2020.

Market Dynamics:

Driver:

Rising prevalence of ophthalmic conditions

One of the key factors contributing to the growing patient population globally is the increasing prevalence of ophthalmic illnesses such as glaucoma, retinal diseases, dry eye disease, and others among the population. The prevalence of various ocular diseases is shown to be higher in the elderly population. Because of the increasing number of efforts carried out by various healthcare agencies, government entities, and market participants, there is a higher diagnostic and treatment rate among the population.

Restraint:

High cost of biologics

Biologics and biosimilars provide various clinical advantages, including increased effectiveness, safety, and others. However, there are several limits, such as the greater cost of biologics, more out-of-pocket spending, and so on. The higher cost of biologics due to their numerous benefits and varied expenditures involved with their research and approvals is a critical issue restricting the use of these medications in developing nations.

Opportunity:

Increasing clinical trials and pipeline candidates for innovative drugs and therapies

Market players and research organisations are putting more emphasis on developing and launching innovative therapies to treat the illness. The increasing efforts of market participants in R&D activities to develop novel medicines for the treatment of the condition are likely to result in a higher demand for ophthalmic disease therapeutics in the market during the forecast period. The increased focus and vigorous efforts of the market's leading competitors to discover and launch novel medicines to meet the unmet demand for the growing patient population is predicted to raise ophthalmic drug consumption.

Threat:

Lack of awareness

Market expansion is hampered by stringent regulatory frameworks and ambiguous reimbursement practises. Lack of awareness of various ocular problems in rural regions, as well as a lack of health insurance that covers all types of IOLs and contact lenses, are limiting market growth. Vision care has become prohibitively expensive, with many individuals all around the world unable to afford ophthalmic procedures. This is regarded as the key cause of the worldwide ophthalmology pharmaceuticals market's diminishing growth.

Covid-19 Impact

Throughout the projection period, the COVID-19 had a negative impact on market growth. One of the key factors responsible for the market's slower growth during the pandemic is the temporary closure of orthopaedic clinics and a greater concentration of healthcare providers on COVID-19 patients. The lockdown restrictions imposed by government authorities across the regions resulted in the cancellation or postponement of services related with many ocular disorders, as well as a decrease in the number of patient visits to hospitals and clinics. This resulted in a decline in global patient demand for ocular illness medicines.

The anti-VEGF segment is expected to be the largest during the forecast period

The anti-VEGF segment is estimated to have a lucrative growth, due to the rising demand and acceptance of anti-VEGF agents, and the presence of significant market players with extensive product portfolios. Furthermore, the segment's growth is attributed to the great performance of Avastin, LUCENTIS, and others. The current class of anti-VEGF medications is effective but not long-lasting, hence the focus of players on the development of therapeutics with longer action is growing.

The semisolid segment is expected to have the highest CAGR during the forecast period

The semisolid segment is anticipated to witness the fastest CAGR growth during the forecast period, because of the increasing number of product approvals and releases, such as ointment, suspensions, gels, and others. Rising applications of ointment including inflammatory conditions, infections, and dry eye due its increased effectiveness is leading to rising adoption of the semisolid products. Together with this, the rising attention of the leading players on gaining approvals and introducing new products is another factor contributing to the segment's rise.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising prevalence of various ocular illnesses combined with higher diagnostic and treatment rate. Furthermore, rising healthcare spending on eye care and eye health in the region, as well as the availability of acceptable reimbursement for various ophthalmic conditions, encourages the adoption of advanced and novel treatments in the region's important countries. A favourable environment for the research and development of numerous revolutionary pharmaceuticals to cure ophthalmic illnesses, as well as the increasing approval of new drugs, are some other factors contributing to the market's growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Increasing biologics and biosimilar launches for the treatment of various eye disorders, increased emphasis on effective ocular condition management, and expanding attempts by market leading players to expand their geographical footprint. The introduction of new products, among other things, is one of the few aspects substantially contributing to market growth. Furthermore, the government's increased investments and advancements in healthcare infrastructure facilities are boosting the market.

Key Players in the market

Some of the key players profiled in the Ophthalmic Disease Therapeutics Market include Bayer AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., AbbVie Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Novartis AG, Eye Pharmaceuticals, Roche Valeant, Merck & Co., Lpath, Alcon Inc., Pfizer Inc. and Senju

Key Developments:

In September 2022, Santen Pharmaceutical Co., Ltd. And UBE received approval from the U.S. FDA for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

In June 2022, F. Hoffmann-La Roche Ltd. Received authorization for Vabysmo, from Health Canada for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

In March 2022, Novartis AG received approval from the European commission for Beovu, an ophthalmic medicine for the treatment of visual impairment caused due to diabetic macular edema.

In February 2022, Viatris Inc. received approval for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis, for the treatment of ocular inflammation.

In December 2021, AbbVie Inc. received approval from the U.S. FDA for Vuity, a pilocarpine Hcl ophthalmic solution for the treatment of presbyopia.

Disease Indications Covered:

  • Retinal Diseases
  • Glaucoma
  • Dry Eye Disease
  • Allergy & Infections
  • Other Disease Indications

Drug Classes Covered:

  • Anti-glaucoma
  • Anti-VEGF
  • Anti-inflammatory
  • Anti-infectives
  • Other Drug Classes

Dosage Forms Covered:

  • Semi-solid
  • Solid
  • Liquid

Distribution Channels Covered:

  • Retail & Online Pharmacies
  • Hospital Pharmacies

End Users Covered:

  • Patients
  • Diagnostic Centres
  • Hospitals
  • Eye Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Ophthalmic Disease Therapeutics Market, By Disease Indication

  • 5.1 Introduction
  • 5.2 Retinal Diseases
    • 5.2.1 Diabetic Macular Edema (DME)
    • 5.2.2 Retinal Vein Occlusion (RVO)
    • 5.2.3 Diabetic Retinopathy (DR)
    • 5.2.4 Macular Degeneration (AMD)
  • 5.3 Glaucoma
    • 5.3.1 Open Angle Glaucoma
    • 5.3.2 Angle Closure Glaucoma
    • 5.3.3 Others
  • 5.4 Dry Eye Disease
  • 5.5 Allergy & Infections
  • 5.6 Other Disease Indications

6 Global Ophthalmic Disease Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Anti-glaucoma
    • 6.2.1 Alpha Adrenergic Agonists
    • 6.2.2 Beta Blockers
    • 6.2.3 Carbonic Anhydrase Inhibitors
    • 6.2.4 Combination Drugs
    • 6.2.5 Prostaglandins Analogs
    • 6.2.6 Others
  • 6.3 Anti-VEGF
  • 6.4 Anti-inflammatory
  • 6.5 Anti-infectives
  • 6.6 Other Drug Classes

7 Global Ophthalmic Disease Therapeutics Market, By Dosage Form

  • 7.1 Introduction
  • 7.2 Semi-solid
  • 7.3 Solid
  • 7.4 Liquid

8 Global Ophthalmic Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail & Online Pharmacies
  • 8.3 Hospital Pharmacies

9 Global Ophthalmic Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Patients
  • 9.3 Diagnostic Centres
  • 9.4 Hospitals
  • 9.5 Eye Clinics

10 Global Ophthalmic Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 F. Hoffmann-La Roche Ltd.
  • 12.3 Regeneron Pharmaceuticals Inc.
  • 12.4 AbbVie Inc.
  • 12.5 Santen Pharmaceutical Co. Ltd.
  • 12.6 Viatris Inc.
  • 12.7 Novartis AG
  • 12.8 Eye Pharmaceuticals
  • 12.9 Roche Valeant
  • 12.10 Merck & Co.
  • 12.11 Lpath
  • 12.12 Alcon Inc.
  • 12.13 Pfizer Inc.
  • 12.14 Senju

List of Tables

  • Table 1 Global Ophthalmic Disease Therapeutics Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Ophthalmic Disease Therapeutics Market Outlook, By Disease Indication (2020-2028) ($MN)
  • Table 3 Global Ophthalmic Disease Therapeutics Market Outlook, By Retinal Diseases (2020-2028) ($MN)
  • Table 4 Global Ophthalmic Disease Therapeutics Market Outlook, By Diabetic Macular Edema (DME) (2020-2028) ($MN)
  • Table 5 Global Ophthalmic Disease Therapeutics Market Outlook, By Retinal Vein Occlusion (RVO) (2020-2028) ($MN)
  • Table 6 Global Ophthalmic Disease Therapeutics Market Outlook, By Diabetic Retinopathy (DR) (2020-2028) ($MN)
  • Table 7 Global Ophthalmic Disease Therapeutics Market Outlook, By Macular Degeneration (AMD) (2020-2028) ($MN)
  • Table 8 Global Ophthalmic Disease Therapeutics Market Outlook, By Glaucoma (2020-2028) ($MN)
  • Table 9 Global Ophthalmic Disease Therapeutics Market Outlook, By Open Angle Glaucoma (2020-2028) ($MN)
  • Table 10 Global Ophthalmic Disease Therapeutics Market Outlook, By Angle Closure Glaucoma (2020-2028) ($MN)
  • Table 11 Global Ophthalmic Disease Therapeutics Market Outlook, By Others (2020-2028) ($MN)
  • Table 12 Global Ophthalmic Disease Therapeutics Market Outlook, By Dry Eye Disease (2020-2028) ($MN)
  • Table 13 Global Ophthalmic Disease Therapeutics Market Outlook, By Allergy & Infections (2020-2028) ($MN)
  • Table 14 Global Ophthalmic Disease Therapeutics Market Outlook, By Other Disease Indications (2020-2028) ($MN)
  • Table 15 Global Ophthalmic Disease Therapeutics Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 16 Global Ophthalmic Disease Therapeutics Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 17 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-glaucoma (2020-2028) ($MN)
  • Table 18 Global Ophthalmic Disease Therapeutics Market Outlook, By Alpha Adrenergic Agonists (2020-2028) ($MN)
  • Table 19 Global Ophthalmic Disease Therapeutics Market Outlook, By Beta Blockers (2020-2028) ($MN)
  • Table 20 Global Ophthalmic Disease Therapeutics Market Outlook, By Carbonic Anhydrase Inhibitors (2020-2028) ($MN)
  • Table 21 Global Ophthalmic Disease Therapeutics Market Outlook, By Combination Drugs (2020-2028) ($MN)
  • Table 22 Global Ophthalmic Disease Therapeutics Market Outlook, By Prostaglandins Analogs (2020-2028) ($MN)
  • Table 23 Global Ophthalmic Disease Therapeutics Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 24 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-VEGF (2020-2028) ($MN)
  • Table 25 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-inflammatory (2020-2028) ($MN)
  • Table 26 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-infectives (2020-2028) ($MN)
  • Table 27 Global Ophthalmic Disease Therapeutics Market Outlook, By Others (2020-2028) ($MN)
  • Table 28 Global Ophthalmic Disease Therapeutics Market Outlook, By Dosage Form (2020-2028) ($MN)
  • Table 29 Global Ophthalmic Disease Therapeutics Market Outlook, By Semi-solid (2020-2028) ($MN)
  • Table 30 Global Ophthalmic Disease Therapeutics Market Outlook, By Solid (2020-2028) ($MN)
  • Table 31 Global Ophthalmic Disease Therapeutics Market Outlook, By Liquid (2020-2028) ($MN)
  • Table 32 Global Ophthalmic Disease Therapeutics Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 33 Global Ophthalmic Disease Therapeutics Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 34 Global Ophthalmic Disease Therapeutics Market Outlook, By Hospital Pharmacies (2020-2028) ($MN)
  • Table 35 Global Ophthalmic Disease Therapeutics Market Outlook, By End User (2020-2028) ($MN)
  • Table 36 Global Ophthalmic Disease Therapeutics Market Outlook, By Patients (2020-2028) ($MN)
  • Table 37 Global Ophthalmic Disease Therapeutics Market Outlook, By Diagnostic Centres (2020-2028) ($MN)
  • Table 38 Global Ophthalmic Disease Therapeutics Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 39 Global Ophthalmic Disease Therapeutics Market Outlook, By Eye Clinics (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.